Orbitrap Fusion Lumos Tribrid Mass Spectrometer wins Scientists’ Choice Award for Best New Drug Discovery Product of 2015
![](/46/pdcnewsitem/03/88/69/Orbitrap_Fusion_Lumos_Front_%26_Top-Easy1.jpg)
This award recognizes the company with the highest reviews and ratings on SelectScience.
The global community of SelectScience readers and contributors has named the Thermo Scientific Orbitrap Fusion Lumos Tribrid Mass Spectrometer the Best New Drug Discovery Product of 2015. This award recognizes the company with the highest reviews and ratings on SelectScience, an online resource that fulfills the information needs of the global scientific community.
SelectScience announced the winner this week at an awards ceremony at the Annual Conference and Exhibition of the Society for Laboratory Automation and Screening (SLAS) in San Diego. Last year, the SelectScience community awarded the Thermo Scientific Vanquish High-Performance Liquid Chromatography system with Best New Separations Product and named Thermo Fisher Scientific as Company of the Year.
“This Scientists’ Choice Award celebrates the new technologies that made the biggest impact in drug discovery and development research in 2015,” said Arif Butt, CEO and founder of SelectScience. “The awards are unique in this industry as they empower scientists to nominate and vote for their favorite new product, enabling them to have their say in the manufacturers that have truly enabled their work. Congratulations to Thermo Fisher Scientific on this significant achievement.”
“We aim to deliver technology innovations that enable our customers to make impactful scientific discoveries,” said Dan Shine, senior vice president, analytical instruments at Thermo Fisher. “Ten years ago, we introduced the first Orbitrap-based mass spectrometer and this opened up new possibilities in life sciences research. Since then, we have continued to deliver new levels of performance for scientists conducting the most challenging work. We are proud that the scientific community recognizes the pioneering contributions of our newest addition, the Orbitrap Fusion Lumos MS.”
Scientists pushing the limits of quantitation and protein characterization require more expansive and in-depth analytical information. The Orbitrap Fusion Lumos Tribrid MS addresses this need for scientists conducting proteomics, biopharma and metabolomics research. The broad advances made in the new-generation Orbitrap Fusion Lumos MS instrument deliver increased sensitivity and an enhanced feature set, allowing scientists to perform more comprehensive sample analyses faster and with better accuracy than our mass spectrometers ever have before.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance